Bioton, Poland's largest biotechnology company will invest $ 35 mn in a joint venture that will operate in India, Finland, Russia and the UK, continuing its international expansion plan.

Bioton, Poland's largest biotechnology company will invest $ 35 million in a joint venture that will operate in India, Finland, Russia and the UK, continuing its international expansion plan. 

The Biotons's principal activity is manufacture of clinically important modern drugs, including recombined human insulin and its pharmaceutical forms, preparations from the cephalosporine, aminoglycoside and macrolide groups. The Group closely co-operates with the Institute of Biotechnology and Antibiotics, which conducts the research of drugs using chemical synthesis and biosynthesis based on genetic engineering methods, and develops technologies of drug manufacturing. The Group has got subsidiaries, located in Poland, Cyprus and Singapore.

Warsaw-based Bioton, which will sell shares to pay for 40 per cent of the deal, announced the venture with companies from the MJ Group late yesterday. Bioton will own 50 percent of the new company.  The venture will give Bioton access to products that are in "advanced phases of development and in the registration process of the European Medicines Agency," helping the company's plans to expand in Western Europe, the company said.